---
layout: post
title: "Emergent Biosolutions Inc.; Withdrawal of Approval of a Supplemental New Drug Application for NARCAN (Naloxone Hydrochloride) Nasal Spray, 2 Milligrams/0.1 Milliliter"
date: 2026-02-05 18:35:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02823
original_published: 2023-02-10 00:00:00 +0000
significance: 8.00
---

# Emergent Biosolutions Inc.; Withdrawal of Approval of a Supplemental New Drug Application for NARCAN (Naloxone Hydrochloride) Nasal Spray, 2 Milligrams/0.1 Milliliter

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 10, 2023 00:00 UTC
**Document Number:** 2023-02823

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing the approval of a supplemental new drug application (sNDA) for NARCAN (naloxone hydrochloride) nasal spray, 2 milligrams (mg)/0.1 milliliter (mL), held by Emergent Biosolutions Inc., 400 Professional Dr., Suite 400, Gaithersburg, MD 20879. Emergent Biosolutions, Inc., has notified the Agency in writing that NARCAN (naloxone hydrochloride) nasal spray, 2 mg/0.1 mL, is not marketed and has requested that approval of the sNDA be withdrawn. This action has no impact on the continued approval and marketing of NARCAN (naloxone hydrochloride) nasal spray, 4 mg/0.1 mL.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/10/2023-02823/emergent-biosolutions-inc-withdrawal-of-approval-of-a-supplemental-new-drug-application-for-narcan)
- API: https://www.federalregister.gov/api/v1/documents/2023-02823

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
